Your browser doesn't support javascript.
Does prior exposure to immune checkpoint inhibitors treatment affect incidence and mortality of COVID-19 among the cancer patients: The systematic review and meta-analysis.
Liu, Yang; Liu, Shuo; Qin, Yujun; Zhao, Lei; Li, Yiliang; Zhou, Chenghui; Chen, Wei.
  • Liu Y; Department of Surgical intensive care unit, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Liu S; Department of Pharmacy, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
  • Qin Y; Department of Intensive care unit, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Zhao L; Department of Intensive care unit, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Li Y; The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China.
  • Zhou C; Department of Anesthesiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Chen W; Department of Intensive care unit, Beijing Shijitan Hospital, Capital Medical University, Beijing, China. Electronic address: cwicu@bjsjth.cn.
Int Immunopharmacol ; 101(Pt A): 108242, 2021 Dec.
Article in English | MEDLINE | ID: covidwho-1458697
ABSTRACT

BACKGROUND:

Immune checkpoint inhibitors (ICIs) treatment among cancer patients has been shown to have antiviral effects by reactivating exhausted T cells. However, they could also trigger inflammatory storm. Therefore, prior exposure to ICIs may influence the risk of SARS-CoV2 infection and subsequent mortality. Recent results from studies of ICIs treatment on incidence and mortality of COVID-19 are controversial. MATERIALS AND

METHODS:

We searched databases PubMed, Embase, ISI of Knowledge, Cochrane Central Register of Controlled Trials (CENTRAL), as well as pre-print databases (MedRxiv and BioRxiv) for retrospective and prospective studies comparing ICIs versus other antitumor treatments in cancer patients in the area of COVID-19 pandemic. The primary outcome was the incidence of COVID-19. The secondary outcomes were mortality of COVID-19.

RESULTS:

Twenty-three studies with a total of 117,735 patients were selected. Compared with other antitumor treatments, prior exposure to ICIs had not an increased risk of incidence [Odds ratio (OR), 0.84; 95% confidence interval (CI), 0.60-1.18; P = 0.32] and mortality (OR, 1.22; 95% CI, 0.91-1.62; P = 0.18) of COVID-19 infectioin. Our subgroup and meta-regression analyses indicated that prior exposure to ICIs may reduce the incidence of COVID-19 in metastatic cancer patients.

CONCLUSIONS:

There was no significant difference on incidence and mortality of COVID-19 between prior exposure to ICIs with other anti-tumor treatments. ICIs may reduce infection susceptibility of COVID-19 in metastatic cancer patients.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immune Checkpoint Inhibitors / COVID-19 / Neoplasms Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Reviews / Systematic review/Meta Analysis Topics: Long Covid Limits: Humans Language: English Journal: Int Immunopharmacol Journal subject: Allergy and Immunology / Pharmacology Year: 2021 Document Type: Article Affiliation country: J.intimp.2021.108242

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Immune Checkpoint Inhibitors / COVID-19 / Neoplasms Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Reviews / Systematic review/Meta Analysis Topics: Long Covid Limits: Humans Language: English Journal: Int Immunopharmacol Journal subject: Allergy and Immunology / Pharmacology Year: 2021 Document Type: Article Affiliation country: J.intimp.2021.108242